EC 213-961-8
Also known as Epilim and valproate.
Two Phase 3 trials found symptom improvement by Day 3, sustained through Week 3; approval would add another adult use.
A second pivotal study found improvement in symptoms by Day 3; the findings will support a planned US regulatory submission.
24 abstracts at Psych Congress will report Phase 3 CAPLYTA data in bipolar mania, SPRAVATO analyses on anhedonia, seltorexant MDD+insomnia results, and LAI real‑world studies.
Network meta-analysis of 10 trials found an adjunctive atypical antipsychotic superior on MADRS change, response, remission and CGI‑S, with no significant weight gain and favorable tolerability.